Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance

Abstract excerpt

The enthusiasm about successful novel therapeutic strategies in cancer is often quickly dampened by the development of drug resistance. This is true for targeted therapies using tyrosine kinase inhibitors for EGFR or BRAF mutant cancers, but is also an increasingly recognized problem for immunotherapies. One of the major obstacles of successful cancer therapy is tumor heterogeneity of genotypic and phenotypic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Cells and Metastasis
• Share to Cancer Genomics and Diagnostics
• Share to Protein Degradation and Inhibitors